Vaborbactam
As of the edition of 20 October 2026, Vaborbactam is a small molecule: marketed, first approved in 2017 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Vabomere
- First approved
- 29 August 2017 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Menarini; 2 holders in all
- Registered trials
- 11, 1 stopped early
- Disease areas
- Infections; Lungs and airways
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 2 | 0 | 2 | 0 |
| Phase 3 | 4 | 2 | 1 | 1 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Menarini | Applicant | 2018 to now |